Skip to main content

Critical Limb Ischemia clinical trials at UCSF

5 in progress, 1 open to eligible people

Showing trials for
  • LIFE-BTK Randomized Controlled Trial

    open to eligible people ages 18 years and up

    Pre-market clinical evaluation of the everolimus eluting Esprit™ BTK System for the planned treatment of narrowed infrapopliteal lesions.

    Fresno, California and other locations

  • Assessing the Feasibility of BGC101 in the Treatment of PAD & CLI

    Sorry, in progress, not accepting new patients

    Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.

    San Francisco, California and other locations

  • Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

    Sorry, in progress, not accepting new patients

    This is a prospective, multicenter, randomized trial to determine the mechanisms of vascular healing. The study will evaluate subjects with peripheral artery disease (PAD) who require an endovascular intervention of the femoro-popliteal (SFA) artery to restore blood flow to the leg.

    San Francisco, California and other locations

  • The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

    Sorry, in progress, not accepting new patients

    Two phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).

    San Francisco, California and other locations

  • The PROMISE II Trial, Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    Sorry, in progress, not accepting new patients

    The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").

    San Francisco, California and other locations

Our lead scientists for Critical Limb Ischemia research studies include .

Last updated: